Krystal Biotech, Inc. Operating Income

Quick Answer

Krystal Biotech, Inc. reported Operating Income of $161.29 million for fiscal year 2025.

Krystal Biotech, Inc. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 $161.29M +145.3%
2024 $65.75M +160.0%
2023 -$109.62M +24.5%
2022 -$145.20M -112.7%
2021 -$68.28M -106.9%
2020 -$33.00M -49.4%
2019 -$22.08M -85.3%
2018 -$11.92M -149.7%
2017 -$4.77M -317.5%
2016 -$1.14M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 $41.37M +84.1% +5.3%
June 30, 2025 $39.31M +358.9% +8.7%
March 31, 2025 $36.18M +641.2% +61.0%
September 30, 2024 $22.47M +186.5% +162.3%
June 30, 2024 $8.57M +122.5% +228.2%
March 31, 2024 -$6.68M +86.3% +74.3%
September 30, 2023 -$25.99M +17.4% +31.7%
June 30, 2023 -$38.05M -32.3% +22.1%
  • Krystal Biotech, Inc. showed an increase of +145.3% in Operating Income compared to the prior fiscal year.
  • Over the 2016–2025 period, Krystal Biotech, Inc.’s operating income has grown by 14211.5% (from -$1.14 million to $161.29 million).
  • The most recent figure is from Krystal Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment